دورية أكاديمية
Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.
العنوان: | Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up. |
---|---|
المؤلفون: | Finall A; Cellular Pathology, Swansea Bay University Health Board, Port Talbot, UK afinall@me.com.; Medical School, Swansea University, Swansea, UK., Davies G; Cellular Pathology, Swansea Bay University Health Board, Port Talbot, UK., Jones T; Cellular Pathology, Swansea Bay University Health Board, Port Talbot, UK., Emlyn G; Cellular Pathology, Betsi Cadwaladr University Health Board, Bangor, UK., Huey P; Cellular Pathology, Betsi Cadwaladr University Health Board, Bangor, UK., Mullard A; Oncology, Betsi Cadwaladr University Health Board, Bangor, UK. |
المصدر: | Journal of clinical pathology [J Clin Pathol] 2023 Jun; Vol. 76 (6), pp. 391-399. Date of Electronic Publication: 2022 Jan 18. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0376601 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-4146 (Electronic) Linking ISSN: 00219746 NLM ISO Abbreviation: J Clin Pathol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: London : BMJ Pub. Group Original Publication: London : British Medical Association |
مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/diagnosis , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/diagnosis , Lung Neoplasms*/genetics , Lung Neoplasms*/drug therapy, Humans ; Retrospective Studies ; Follow-Up Studies ; Mutation ; Polymerase Chain Reaction ; ErbB Receptors/genetics ; High-Throughput Nucleotide Sequencing ; United Kingdom |
مستخلص: | Aims: Somatic genetic testing in non-squamous, non-small cell lung carcinoma (NSCLC) patients is required to highlight subgroups eligible for a number of novel oncological therapies. This study aims to determine whether turnaround times for reporting epidermal growth factor receptors (EGFR) by next-generation sequencing (NGS) alone is sufficient to meet the needs of lung cancer patients. Methods: We performed a retrospective case series with follow-up. Outcomes of EGFR testing (102 tests) in 96 patients by NGS were compared with a rapid, fully automated PCR-based platform (Idylla) in local histopathology laboratories. Results: Turnaround time for reporting NGS was 17 calendar days. Reporting using the Idylla EGFR Mutation Test, by contrast, gave a potential turnaround time of 3.8 days from request to authorisation. Three-quarters of patients presenting with stage IV disease had a performance status of 0, 1, or 2 but 18% experienced rapid clinical deterioration (p<0.05). A third of these patients were deceased by the time NGS reports were available. Conclusions: We discuss issues around integrating rapid PCR testing alongside NGS in multidisciplinary care pathways and strategies for mitigating against foreseeable difficulties. Dual testing for stage IV non-squamous, NSCLC patients has the potential to improve care and survival outcomes by providing access to the right test at the right time. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.) |
فهرسة مساهمة: | Keywords: genes; lung neoplasms; medical oncology; neoplasm; pathology; polymerase chain reaction; surgical |
المشرفين على المادة: | EC 2.7.10.1 (ErbB Receptors) |
تواريخ الأحداث: | Date Created: 20220119 Date Completed: 20230522 Latest Revision: 20230522 |
رمز التحديث: | 20230522 |
DOI: | 10.1136/jclinpath-2021-207987 |
PMID: | 35042754 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1472-4146 |
---|---|
DOI: | 10.1136/jclinpath-2021-207987 |